These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Chapman RW; Stanghellini V; Geraint M; Halphen M Am J Gastroenterol; 2013 Sep; 108(9):1508-15. PubMed ID: 23835436 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older. Menees SB; Franklin H; Chey WD Clin Ther; 2020 Jul; 42(7):1406-1414.e4. PubMed ID: 32660770 [TBL] [Abstract][Full Text] [Related]
25. A double-blind trial of a celandin, aloevera and psyllium laxative preparation in adult patients with constipation. Odes HS; Madar Z Digestion; 1991; 49(2):65-71. PubMed ID: 1800188 [TBL] [Abstract][Full Text] [Related]
26. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial. Chey WD; Lembo AJ; Rosenbaum DP Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495 [TBL] [Abstract][Full Text] [Related]
27. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635 [TBL] [Abstract][Full Text] [Related]
28. Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation. Ballou S; Beath A; Kaptchuk TJ; Hirsch W; Sommers T; Nee J; Iturrino J; Rangan V; Singh P; Jones M; Lembo A Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1738-1744.e1. PubMed ID: 29654913 [TBL] [Abstract][Full Text] [Related]
29. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome]. Tegaserod Clinical Research Group Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial. Fukudo S; Nakamura M; Hamatani T; Kazumori K; Miwa H Clin Gastroenterol Hepatol; 2021 Mar; 19(3):538-546.e8. PubMed ID: 32184185 [TBL] [Abstract][Full Text] [Related]
31. Influence of Lactitol and Psyllium on Bowel Function in Constipated Indian Volunteers: A Randomized, Controlled Trial. Cheng J; Tennilä J; Stenman L; Ibarra A; Kumar M; Gupta KK; Sharma SS; Sen D; Garg S; Penurkar M; Kumar S; Ouwehand AC Nutrients; 2019 May; 11(5):. PubMed ID: 31117218 [TBL] [Abstract][Full Text] [Related]
32. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769 [TBL] [Abstract][Full Text] [Related]
34. The effect of green kiwifruit on gas transit and tolerance in healthy humans. Caballero N; Benslaiman B; Ansell J; Serra J Neurogastroenterol Motil; 2020 Sep; 32(9):e13874. PubMed ID: 32431019 [TBL] [Abstract][Full Text] [Related]
35. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. Nakajima A; Seki M; Taniguchi S J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422 [TBL] [Abstract][Full Text] [Related]
36. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. Johnston JM; Shiff SJ; Quigley EM Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977 [TBL] [Abstract][Full Text] [Related]
37. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Fukudo S; Hongo M; Kaneko H; Ueno R Neurogastroenterol Motil; 2011 Jun; 23(6):544-e205. PubMed ID: 21303430 [TBL] [Abstract][Full Text] [Related]
39. Systematic review with meta-analysis: lubiprostone efficacy on the treatment of patients with constipation. Passos MDCF; Takemoto MLS; Corradino GC; Guedes LS Arq Gastroenterol; 2020; 57(4):498-506. PubMed ID: 33331483 [TBL] [Abstract][Full Text] [Related]
40. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Evans BW; Clark WK; Moore DJ; Whorwell PJ Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]